Get started
Author

Cristina Guerrero Páez

Observed names: C Guerrero Paez, C. Guerrero Paez, C. Guerrero Páez, C. Guerrero-Paez, Cristina Guerrero Paez, Guerrero Paez, Cristina
ORCID: 0009-0002-3101-3771
Observed ORCID: 0009-0002-3101-3771
OpenAlex ID: A5083927636
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study
2021 · Anouk H. Eijkelboom, Linda de Munck, et al. · Journal of Hematology & Oncology · 152
PDF
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
2024 · Gabe S. Sonke, Annemiek van Ommen-Nijhof, et al. · Nature · 78
Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic
2021 · Anouk H. Eijkelboom, Linda de Munck, et al. · Preventive Medicine · 65
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
2026 · Noor Wortelboer, Annemiek van Ommen-Nijhof, et al. · JAMA Oncology · 12
Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design
2023 · A. Klaassen-Dekker, C. H. C. Drossaert, et al. · BMC Cancer · 12
PDF
High-impact complications after breast cancer surgery in the Dutch national quality registry: evaluating case-mix adjustment for hospital comparisons
2024 · Elfi M Verheul, David van Klaveren, et al. · BJS Open · 5
PDF
Let's talk about sex! Why should healthcare professionals address sexual distress in breast cancer patients and survivors?
2024 · Anouk S. Huberts, Noëlle J.M.C. Vrancken Peeters, et al. · European Journal of Oncology Nursing · 5
PDF
487MO Overall survival with first versus second-line use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer
2025 · N. Wortelboer, A. Van Ommen-Nijhof, et al. · Annals of Oncology · 4
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
2025 · Noor Wortelboer, Seamus Kent, et al. · European Journal of Cancer · 3
PDF
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
2025 · Noor Wortelboer, Seamus Kent, et al. · JNCI Journal of the National Cancer Institute · 2
Different needs ask for different care: Breast cancer patients’ preferences regarding assessment of care needs and information provision in personalized aftercare
2025 · A. Dekker-Klaassen, C.H.C. Drossaert, et al. · European Journal of Oncology Nursing · 2
PDF
352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
2024 · N. Wortelboer, S. Kent, et al. · Annals of Oncology · 2
PDF
Quality indicators for breast reconstruction following cancer—an international Delphi consensus study supported by the European Society of Plastic, Reconstructive and Aesthetic Surgery
2025 · Emma Hansson, Nicholas Moellhoff, et al. · BJS Open · 1
PDF
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
2025 · Gabe S. Sonke, Annemiek van Ommen-Nijhof, et al. · Nature · 1
PDF
An Information Tool Incorporating Real-World Outcome Data for Women With Metastatic Breast Cancer Eligible for Treatment With a CDK4/6 Inhibitor: Development and Evaluation
2026 · Ellen G Engelhardt, Mariska Q N Hackert, et al. · JMIR Cancer
Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision‐Making in Dutch Breast Cancer Patients: A Population‐Based Study
2026 · Joyce Meijer, Nienke Hermanns, et al. · International Journal of Cancer
Impact of reimbursement on the utilisation of gene expression profiles and chemotherapy decision-making in Dutch breast cancer patients: A population-based study
2026 · J. Meijer, N. Hermanns, et al. · European Journal of Cancer
Late adverse effects after breastcancer (treatment) a survey study has proven our hypothesis that late adverse effects of breastcancer(treatment) can hinder quality of life. There's too little attention in consultation rooms; patients should be information about possible effects before the start of their treatment. Knowledge about late adverse effects, such as those of new treatments, is also needed. We want to raise awareness among patients, professionals, researchers and policymakers
2026 · A. Arps, C. Guerrero Paez · European Journal of Cancer
364TiP Early detection of symptoms during chemo(immune)therapy treatment of metastatic breast cancer using ePRO and Fitbits: The SYMPHA trial
2025 · L. Woudstra, M. Mulder, et al. · ESMO Real World Data and Digital Oncology
Abstract PS2-04: Health related quality of life with first- versus second-line CDK4/6 inhibitor use in advanced breast cancer: results from the phase 3 SONIA trial (BOOG 2017-03)
2025 · Noor Wortelboer, Seamus Kent, et al. · Clinical Cancer Research
EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)
2024 · S Kent, N Wortelboor, et al. · Value in Health
PDF
Abstract P4-07-17: Follow-up in breast cancer care: guidelines and individual risks
2023 · Lotte Van Dongen, Joyce Meijer, et al. · Cancer Research
Abstract S02-02: The impact of resuming the breast cancer screening program in the Netherlands on breast cancer incidence and stage after its discontinuation due to the COVID-19 pandemic
2021 · Anouk H. Eijkelboom, Linda de Munck, et al. · Clinical Cancer Research
Abstract PS7-88: Effect of the COVID-19 pandemic on the initial treatment of breast cancer in the Netherlands: A population-based study
2021 · Anouk H Eijkelboom, Linda de Munck, et al. · Cancer Research
Works count: 25
Citation count: 343
H-index: 5
I10-index: 5
Year
Topic
Type